518. Characterization of colistin-resistant (COL-R) Acinetobacter baumannii calcoaceticus complex (ABC) isolates from a recent, global Phase 3 trial (ATTACK)

por Moussa, Samir, McLeod, Sarah, Miller, Alita
Publicado 2022

2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam

por McLeod, Sarah, Carter, Nicole, Moussa, Samir, Miller, Alita
Publicado 2023

694. In vitro Antibacterial Activity of Sulbactam–Durlobactam (ETX2514SUL) Against 121 Recent Acinetobacter baumannii Isolated from Patients in India

por Miller, Alita, McLeod, Sarah, Mathur, Tarun, Morrissey, Ian
Publicado 2019

1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East

por Miller, Alita, McLeod, Sarah, Moussa, Samir, Hackel, Meredith
Publicado 2020

1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates

por McLeod, Sarah, Moussa, Samir, Hackel, Meredith, Miller, Alita
Publicado 2020

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species

por Papp-Wallace, Krisztina M, McLeod, Sarah M, Miller, Alita A
Publicado 2023

85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in...

por Miller, Alita, McLeod, Sarah, Shapiro, Adam B, Rana, Khurram, Altarac, David
Publicado 2023

709. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam–Durlobactam (ETX2514SUL) Against Pathogenic Burkholderia Species

por O’Donnell, John, Miller, Alita, Lane, Douglas, Panchal, Rekha, Mueller, John P
Publicado 2019

1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)

por Dousa, Khalid M, Kurz, Sebastian G, Bethel, Christopher, Miller, Alita, Bonomo, Robert A
Publicado 2020

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

por Karlowsky, James A., Hackel, Meredith A., McLeod, Sarah M., Miller, Alita A.
Publicado 2022

Regulation of Staphylococcus aureus MntC Expression and Its Role in Response to Oxidative Stress

por Handke, Luke D., Hawkins, Julio C., Miller, Alita A., Jansen, Kathrin U., Anderson, Annaliesa S.
Publicado 2013

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

por Shapiro, Adam B., Moussa, Samir H., McLeod, Sarah M., Durand-Réville, Thomas, Miller, Alita A.
Publicado 2021

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

por Anderson, Annaliesa S., Miller, Alita A., Donald, Robert G.K., Scully, Ingrid L., Nanra, Jasdeep S., Cooper, David, Jansen, Kathrin U.
Publicado 2012

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Py...

por Sagan, Olexiy, Yakubsevitch, Ruslan, Yanev, Krassimir, Fomkin, Roman, Stone, Emily, Hines, Daniel, O’Donnell, John, Miller, Alita, Isaacs, Robin, Srinivasan, Subasree
Publicado 2020

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii

por Moussa, Samir H., Shapiro, Adam B., McLeod, Sarah M., Iyer, Ramkumar, Carter, Nicole M., Tsai, Yu-Kuo, Siu, L. Kristopher, Miller, Alita A.
Publicado 2023

LpxC Inhibitors as New Antibacterial Agents and Tools for Studying Regulation of Lipid A Biosynthesis in Gram-Negative Pathogens

por Tomaras, Andrew P., McPherson, Craig J., Kuhn, Michael, Carifa, Arlene, Mullins, Lisa, George, David, Desbonnet, Charlene, Eidem, Tess M., Montgomery, Justin I., Brown, Matthew F., Reilly, Usa, Miller, Alita A., O’Donnell, John P.
Publicado 2014

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam...

por Bhavnani, Sujata M, Bhavnani, Sujata M, Bhavnani, Sujata M, Rubino, Christopher M, Hammel, Jeffrey P, Cammarata, Anthony P, Larson, Kajal, Liolios, Kathryn, McLeod, Sarah, Miller, Alita, Ambrose, Paul G, Tommasi, Ruben, O'Donnell, John
Publicado 2022

Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action

por Dousa, Khalid M., Nguyen, David C., Kurz, Sebastian G., Taracila, Magdalena A., Bethel, Christopher R., Schinabeck, William, Kreiswirth, Barry N., Brown, Sheldon T., Boom, W. Henry, Hotchkiss, Richard S., Remy, Kenneth E., Jacono, Frank J., Daley, Charles L., Holland, Steven M., Miller, Alita A., Bonomo, Robert A.
Publicado 2022

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

por Durand-Réville, Thomas F., Comita-Prevoir, Janelle, Zhang, Jing, Wu, Xiaoyun, May-Dracka, Tricia L., Romero, Jan Antoinette C., Wu, Frank, Chen, April, Shapiro, Adam B., Carter, Nicole M., McLeod, Sarah M., Giacobbe, Robert A., Verheijen, Jeroen C., Lahiri, Sushmita D., Sacco, Michael D., Chen, Yu, O’Donnell, John P., Miller, Alita A., Mueller, John P., Tommasi, Rubén A.
Publicado 2020